The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. (Q37209533)

19 August 2017

1 reference

title

The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. (English)

1 reference

19 August 2017

1 reference

Aleix Prat

1

1 reference

19 August 2017

José Baselga

series ordinal

2

1 reference

19 August 2017

publication date

8 July 2008

1 reference

Nature Clinical Practice Oncology

19 August 2017

published in

1 reference

19 August 2017

volume

5

1 reference

19 August 2017

issue

9

1 reference

19 August 2017

page(s)

531-542

1 reference

In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

21 January 2018

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Estimates of the cancer incidence and mortality in Europe in 2006.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Estrogen-receptor biology: continuing progress and therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Mechanisms of tamoxifen resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Endocrine-responsive breast cancer and strategies for combating resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Common and distinct elements in cellular signaling via EGF and FGF receptors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Overexpression of ErbB2 in cancer and ErbB2-targeting strategies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Mechanism of action of trastuzumab and scientific update

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Trastuzumab for early breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Antimitotic Activity of the Potent Tumor Inhibitor Maytansine

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

HSP90 and the chaperoning of cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Selective estrogen receptor modulators: structure, function, and clinical use.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Estrogen receptor pathways to AP-1.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Identification and characterization of a negative regulatory element within the epidermal growth factor receptor gene first intron in hormone-dependent breast cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Novel estrogen receptor coregulators and signaling molecules in human diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Steroid hormone receptor signaling in tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Coregulator function: a key to understanding tissue specificity of selective receptor modulators

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Estrogen receptor-alpha regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Src is an initial target of sex steroid hormone action

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Aromatase inhibitors for breast cancer: lessons from the laboratory

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Clinical trials of intracellular signal transductions inhibitors for breast cancer--a strategy to overcome endocrine resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Overcoming endocrine therapy resistance by signal transduction inhibition

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Trastuzumab--mechanism of action and use in clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1179

7 January 2021

Identifiers

DOI

10.1038/NCPONC1179

1 reference

Dimensions Publication ID

19 August 2017

1050871905

0 references

1 reference